Knowthestock.com
CLSN - Celsion Corp

Sell

Weak GrowthEarnings/Profit is Negative

23%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 0.0%
Operating Income is Negative
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -3912.02%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 8.77
Debt Ratio is 0.25
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.08
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Celsion Corp (CLSN) - www.celsion.com
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Michael Tardugno
Employees - 27
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.